Recent developments in the use of vitamin D analogues

被引:39
作者
Verstuyf, A [1 ]
Segaert, S [1 ]
Verlinden, L [1 ]
Bouillon, R [1 ]
Mathieu, C [1 ]
机构
[1] UZ Gasthuisberg Onderwijs Navorsing, LEGENDO, B-3000 Louvain, Belgium
关键词
1,25-dihydroxyvitamin D-3; analogues; cancer; immune disorders; skin;
D O I
10.1517/13543784.9.3.443
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The non-classical effects of 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) create possible therapeutic applications for immune modulation (e.g., autoimmune diseases and graft rejection), inhibition of cell proliferation (e.g., psoriasis, cancer) and induction of cell differentiation (e.g., cancer). The major drawback related to the use of 1 alpha,25(OH)(2)D-3 is its calcaemic effect, which prevents the application of pharmacological concentrations. Intensive research has led to the development of analogues of 1 alpha,25(OH)(2)D-3 characterised by a clear dissociation-of the antiproliferative and prodifferentiating capacity from the calcaemic effects. Due to this dissociation, these analogues can be used not only for the treatment of bone disorders but also for non-classical applications. In the present review, a summary is given on the use of the 1 alpha,25(OH)(2)D-3 analogues for the treatment of cancer, skin and immune disorders and for the prevention of graft rejection. Moreover a brief overview is given on the use of analogues for secondary hyperparathyroidism.
引用
收藏
页码:443 / 455
页数:13
相关论文
共 123 条
[1]  
ABDAIMI KE, 1999, CANCER RES, V59, P3325
[2]   DIFFERENTIATION OF MOUSE MYELOID-LEUKEMIA CELLS INDUCED BY 1-ALPHA,25-DIHYDROXYVITAMIN-D3 [J].
ABE, E ;
MIYAURA, C ;
SAKAGAMI, H ;
TAKEDA, M ;
KONNO, K ;
YAMAZAKI, T ;
YOSHIKI, S ;
SUDA, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (08) :4990-4994
[3]  
ABE J, 1990, P146
[4]   A NOVEL VITAMIN-D3 ANALOG, 22-OXA-1,25-DIHYDROXYVITAMIN-D3, INHIBITS THE GROWTH OF HUMAN BREAST-CANCER INVITRO AND INVIVO WITHOUT CAUSING HYPERCALCEMIA [J].
ABE, J ;
NAKANO, T ;
NISHII, Y ;
MATSUMOTO, T ;
OGATA, E ;
IKEDA, K .
ENDOCRINOLOGY, 1991, 129 (02) :832-837
[5]  
ABEHASHIMOTO J, 1993, CANCER RES, V53, P2534
[6]  
ANZANO MA, 1994, CANCER RES, V54, P1653
[7]  
Aoki T, 1998, BRIT J DERMATOL, V139, P897
[8]  
Barker JNWN, 1999, BRIT J DERMATOL, V141, P274
[9]   VITAMIN-D, CALCIUM, AND EPIDERMAL DIFFERENTIATION [J].
BIKLE, DD ;
PILLAI, S .
ENDOCRINE REVIEWS, 1993, 14 (01) :3-19
[10]   1,25-Dihydroxyvitamin D-3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G(1) [J].
Blutt, SE ;
Allegretto, EA ;
Pike, JW ;
Weigel, NL .
ENDOCRINOLOGY, 1997, 138 (04) :1491-1497